TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Abbisko Cayman Limited ( (HK:2256) ) has shared an announcement.
Abbisko Cayman Limited announced an increase in shareholding by its founder and CEO, Dr. Xu Yao-Chang, who purchased 17,000 ordinary shares, bringing his total shareholding to approximately 11.77% of the company. This move reflects Dr. Xu’s confidence in the company’s growth prospects. Additionally, the company has been executing a share repurchase plan, buying back 8,695,000 shares to date, which the board believes will enhance shareholder value as the current trading price undervalues the company’s intrinsic worth.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a company incorporated in the Cayman Islands, primarily engaged in the pharmaceutical industry. The company focuses on the development of innovative therapies and has a market presence in Hong Kong, where its shares are traded on the stock exchange.
Average Trading Volume: 5,582,617
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.07B
Learn more about 2256 stock on TipRanks’ Stock Analysis page.